Skip to content
DefDex

Federal award

EXELAN PHARMACEUTICALS INC

SPE2D219D0075

Contract vehicle (IDV)IDV: ceiling is not spending

Obligated and Ceiling

Obligated (net)
$0.00
Vehicle ceiling (not spending)
$40,400,530.45
Current value
—
Gross positive obligations
$0.00

Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.

Award Details

Recipient
EXELAN PHARMACEUTICALS INC · FYZXNHSQTMG8
Owner company
Not a reviewed companyNo reviewed company owns this recipient.
Reported parent
CIPLA USA INC. · MVGMCHRNA7M8
Awarding agency
Department of Defense · sub-agency 97AS · office SPE2D2
Funding agency
Department of Defense · sub-agency 97AS
Product or service (PSC)
6505 · DRUGS AND BIOLOGICALS
Industry (NAICS)
325411 · MEDICINAL AND BOTANICAL MANUFACTURING
PIID
SPE2D219D0075
Award type code
B
Actions
11 · Jul 1, 2019 to May 21, 2024
Why it is listed
contract vehicle (IDV)

Open this award on USAspending →

Action History11

Award actions
DateFYModAction typeObligationCompany in company totals
May 21, 2024FY2024P00010D$0.00
—
Aug 31, 2023FY2023P00009M$0.00
—
Jul 10, 2023FY2023P00008D$0.00
—
Jun 22, 2023FY2023P00007G$0.00
—
Jun 27, 2022FY2022P00006G$0.00
—
Jun 29, 2021FY2021P00005G$0.00
—
Aug 12, 2020FY2020P00004M$0.00
—
Jun 25, 2020FY2020P00003G$0.00
—
Jul 11, 2019FY2019P00002M$0.00
—
Jul 8, 2019FY2019P00001M$0.00
—
Jul 1, 2019FY20190—$0.00
—

Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.